Edgar Filing: INTROGEN THERAPEUTICS INC - Form 4

INTROGEN Form 4 August 30, 2	THERAPEUTIC	CS INC									
FORM									OMB AF	PROVAL	
		ATTIES A			NGE C	COMMISSION	OMB Number:	3235-0287			
Check thi if no long									Expires:	January 31, 2005	
subject to	STATEN						ES IN BENEFICIAL OWNERSHIP O ECURITIES				
Section 1 Form 4 or			burden hou								
Form 5 Filed pursuant to Section 16(a) of the Securities					response 0.5 es Exchange Act of 1934						
obligation may cont	18 Section 17(•	1935 or Section	ı		
See Instru		30(h)	of the In	vestment	Company	Act	of 194	0			
1(b).											
(Print or Type Responses)											
A mantin Inc				Name and	Ticker or T	Fradin	g	5. Relationship of Reporting Person(s) to Issuer			
rivenus me.			Symbol	GEN THE	RAPEU	TICS	INC				
	[INGN]			1105	пче	(Check all applicable)					
(Last)	(First) (I	Middle)	3. Date of	Earliest Tra	insaction			Director	10% Owner		
				onth/Day/Year)				Officer (give titleX Other (specify below) below)			
3711 KENNETT PIKE, SUITE 200, 0				006				10% owner and beneficial owner			
			4. If Amendment, Date Original					6. Individual or Joint/Group Filing(Check			
			Filed(Mon	th/Day/Year)				Applicable Line) Form filed by One Reporting Person			
GREENVILLE, DE 19807									More than One Reporting		
(City)	(State)	(Zip)	Tabl	e I - Non-D	erivative S	ecuri	ties Acq	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of	2. Transaction Date		med 3. 4. Securities Acquired n Date, if Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5)					5. Amount of 6. Ownership 7. Natur Securities Form: Direct Indirect			
Security (Instr. 3)	(Month/Day/Year)	any						Securities Beneficially	Beneficial		
· · /			Day/Year)	(Instr. 8)				Owned	D) or indirect (I)	Ownership	
								Following Reported	(Instr. 4)	(Instr. 4)	
						(A) or		Transaction(s)			
				Code V	Amount	(D)	Price	(Instr. 3 and 4)			
Common	08/28/2006			S	36,739	D	\$ 3.91	3,835,055	I	SFN (1)	
Common	08/29/2006			S	13,484	D	\$ 3.89	3,821,571	I	SFN (2)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: INTROGEN THERAPEUTICS INC - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	(Month/Day/Year) tive ies ed ed 3,		Amou Unde Secur	le and unt of rlying rities . 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Own Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships							
F8	Director	10% Owner	Officer	Other				
Aventis Inc. 3711 KENNETT PIKE, SUITE 200 GREENVILLE, DE 19807)			10% owner and beneficial owner				
AVENTIS HOLDINGS INC 3711 KENNETT PIKE SUITE 200 GREENVILLE, DE 19807				10% owner and beneficial owner				
Signatures								
Kathleen A. Winter, President	08/30/2006							
**Signature of Reporting Person	Date							
Kathleen A. Winter, President	08/30/2006							
**Signature of Reporting Person	Date							

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

For reporting person Aventis Holdings Inc., reflects ownership of (i) 1,491,334 shares of common stock owned directly by Aventis
(1) Holdings Inc., and (ii) 2,343,721 shares of common stock owned by its subsidiary Aventis Pharmaceuticals Inc. For reporting person Aventis Inc., reflects ownership of shares owned directly by Aventis Holdings Inc. and Aventis Pharmaceuticals Inc.

For reporting person Aventis Holdings Inc., reflects ownership of (i) 1,477,850 shares of common stock owned directly by Aventis
(2) Holdings Inc., and (ii) 2,343,721 shares of common stock owned by its subsidiary Aventis Pharmaceuticals Inc. For reporting person Aventis Inc., reflects ownership of shares owned directly by Aventis Holdings Inc. and Aventis Pharmaceuticals Inc.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Edgar Filing: INTROGEN THERAPEUTICS INC - Form 4

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.